TD139

Status
Phase 2
Condition
Idiopathic Pulmonary Fibrosis
Intervention Type
Inhaled Drug
Funder Type
Industry

Drug Details

TD139 is a galectin-3 inhibitor administered by dry powder inhalation.

Study Purpose

This is a randomized, double-blind, placebo-controlled phase 2b trial in subjects with IPF (idiopathic pulmonary fibrosis) investigating the efficacy and safety of TD139.

Find a Clinical Trial

 

footer_txt_bblBook a PFF Ambassador for your event.   Call 844.TalkPFF >